Literature DB >> 947326

[Pharmacokinetic studies with the combination sulfamoxole/trimethoprim in animals and men (author's transl)].

J Kuhne, F W Kohlmann, J K Seydel, E Wempe.   

Abstract

The pharmacokinetics of the 5:1 combination of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (thrimethoprim) (CN 3123, Nevin, Supristol) corresponds to the well known data of the single substances. Investigations on blood level, concentration in plasma water and excretion via urine and bile were done on experimental animals and with therapeutic dosage (single and repeated administration) on men. There were no alterations of the kinetics of the single substances due to drug interaction during simultaneous administration, neither qualitatively nor quantitatively. The dosage schedule elaborated is as follows: dosage interval=12 h, ratio initial dose: maintenance dose=2:1. For adults this regimen with a maintenance dose of 400 mg sulfamoxole and 80 mg trimethoprim results in a steady state of the minimal concentrations immediately before the following dose. These minimal concentrations in plasma water exceed the minimal inhibitory concentrations determined in vitro for most pathogens by several times.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 947326

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

1.  Synergistic antibacterial activity in vitro of trimethoprim and sulphonamides and the importance of pharmacokinetic properties for optimal therapy.

Authors:  J K Seydel; E Wempe
Journal:  Infection       Date:  1979       Impact factor: 3.553

2.  Comparative pharmacokinetics of co-trifamole and co-trimoxazole to 'steady state' in normal subjects.

Authors:  I D Watson; H N Cohen; M J Stewart; S J McIntosh; A Shenkin; J A Thomson
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

4.  Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis.

Authors:  M L Grayson; C Thauvin-Eliopoulos; G M Eliopoulos; J D Yao; D V DeAngelis; L Walton; J L Woolley; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

5.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

Review 6.  The pharmacokinetics of trimethoprim and trimethoprim/sulphonamide combinations, including penetration into body tissues.

Authors:  D S Reeves; P J Wilkinson
Journal:  Infection       Date:  1979       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.